|LRRK2 is one of the most important drug targets in Parkinson's research. In promising news, a San Francisco biotech recently announced the development of a therapeutic program for the LRRK2 gene. Forbes covered the story and featured the Foundation's role in this new effort.|
|Read More >|
How Doctors Choose Parkinson's Medications
Hear expert discussion, and ask questions in our Third Thursdays Webinar series.
September 15 at 12 p.m. ET